New Diagnostic Tests: Breakthrough Approaches or Expensive Add-ons?

Annals of Internal Medicine

Volumn 139, Issue 11, 2003, Pages 950-951

  Deyo, Richard A ^a,b   Jarvik, Jeffrey J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Center for Cost and Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINUM LYMPH NODE; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING;

EID: 1642453776     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-139-11-200312020-00014     Document Type: Review

References (12)

1. Fineberg HV, Bauman R, Sosman M. Computerized cranial tomography. Effect on diagnostic and therapeutic plans. JAMA. 1977;238:224-7. [PMID: 406427]
2. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11:88-94. [PMID: 1907710]
3. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer. A meta-analysis. Ann Intern Med. 2003;139:879-92.
4. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation. Ann Intern Med. 2002;137:598-602. [PMID: 12353947]
5. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926-30. [PMID: 692598]
6. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg. 1998; 66:1876-83; discussion 1883-5. [PMID: 9930463]
7. Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach KW, et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med. 2000;27:1598-609. [PMID: 11105815]
8. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA. 2000;283:1151-8. [PMID: 10703777]
9. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-7. [PMID: 9187198]
10. Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ. 1986;134: 587-94. [PMID: 3512062]
11. Hull RD, Hirsh J, Carter CJ, Jay RM, Ockelford PA, Buller HR, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. A randomized trial. Ann Intern Med. 1985;102:21-8. [PMID: 3881068]
12. Jarvik JG, Hollingworth W, Martin B, Emerson SS, Gray DT, Overman S, et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA. 2003;289:2810-8. [PMID: 12783911]